Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

The goal of this type of clinical trial study is to evaluate the safety and efficacy of Pamiparib combined with Surufatinib as a new neoadjuvant therapy in newly diagnosed patients with advanced ovarian cancer.

Trial Details

NCT ID
NCT05652283
Phase
PHASE2
Sponsor
Bai-Rong Xia
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Pamiparib
  • Surufatinib
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083

Key Eligibility Criteria

  • Before any procedure of the test is started, informed consent must be provided and filed in the research center.
  • Female subjects ≥ 18 years of age.
  • Biopsy obtained by open surgery, laparoscopic surgery or thick needle puncture, pathologically confirmed as high-grade serous or endometrioid ovari…
  • Detect tissue samples or blood samples through a testing agency designated by the research center to determine the HRR-related gene mutation or HRD…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →